Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Fred Saad

Showing results (321-330 of 1,126) with videos related to

Pageof 113
Sort By:
British Journal of Cancer|April 8, 2021
Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progressionJean-Philippe Emond, Louis Lacombe, Patrick Caron, et al.
European Journal of Cancer (Oxford, England : 1990)|September 16, 2018
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysisSusan Feyerabend, Fred Saad, Tracy Li, et al.
Urologic Oncology|October 27, 2019
Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysisSophie Knipper, Carlotta Palumbo, Angela Pecoraro, et al.
Journal of the National Cancer Institute|October 3, 2002
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaFred Saad, Donald M Gleason, Robin Murray, et al.
International Urology and Nephrology|September 23, 2019
External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patientsSophie Knipper, Cristina Dzyuba-Negrean, Carlotta Palumbo, et al.
Future Oncology (London, England)|November 28, 2025
A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastasesBertrand Tombal, Fred Saad, Enrique Gallardo, et al.
European Urology|October 4, 2020
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer MonitoringFred Saad, Cora N Sternberg, Eleni Efstathiou, et al.
Advances in Therapy|September 15, 2023
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate CancerNeal D Shore, Bryan A Mehlhaff, Michael S Cookson, et al.
Cancer|February 8, 2017
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxelAndrew J Armstrong, Fred Saad, De Phung, et al.
British Journal of Cancer|November 8, 2022
Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancerMichèle Rouleau, Flora Nguyen Van Long, Véronique Turcotte, et al.
Pageof 113

Showing results (321-330 of 1,126) with videos related to

Sort By:
Pageof 113
British Journal of Cancer|April 8, 2021
Urinary oestrogen steroidome as an indicator of the risk of localised prostate cancer progressionJean-Philippe Emond, Louis Lacombe, Patrick Caron, et al.
European Journal of Cancer (Oxford, England : 1990)|September 16, 2018
Survival benefit, disease progression and quality-of-life outcomes of abiraterone acetate plus prednisone versus docetaxel in metastatic hormone-sensitive prostate cancer: A network meta-analysisSusan Feyerabend, Fred Saad, Tracy Li, et al.
Urologic Oncology|October 27, 2019
Survival outcomes of radical prostatectomy vs. external beam radiation therapy in prostate cancer patients with Gleason Score 9-10 at biopsy: A population-based analysisSophie Knipper, Carlotta Palumbo, Angela Pecoraro, et al.
Journal of the National Cancer Institute|October 3, 2002
A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinomaFred Saad, Donald M Gleason, Robin Murray, et al.
International Urology and Nephrology|September 23, 2019
External beam radiation therapy improves survival in high- and intermediate-risk non-metastatic octogenarian prostate cancer patientsSophie Knipper, Cristina Dzyuba-Negrean, Carlotta Palumbo, et al.
Future Oncology (London, England)|November 28, 2025
A plain language summary of the EORTC 1333/PEACE-3 study of enzalutamide alone vs enzalutamide plus radium-223 in patients with metastatic castrationresistant prostate cancer (mCRPC) and bone metastasesBertrand Tombal, Fred Saad, Enrique Gallardo, et al.
European Urology|October 4, 2020
Prostate-specific Antigen Progression in Enzalutamide-treated Men with Nonmetastatic Castration-resistant Prostate Cancer: Any Rise in Prostate-specific Antigen May Require Closer MonitoringFred Saad, Cora N Sternberg, Eleni Efstathiou, et al.
Advances in Therapy|September 15, 2023
Impact of Concomitant Cardiovascular Therapies on Efficacy and Safety of Relugolix vs Leuprolide: Subgroup Analysis from HERO Study in Advanced Prostate CancerNeal D Shore, Bryan A Mehlhaff, Michael S Cookson, et al.
Cancer|February 8, 2017
Clinical outcomes and survival surrogacy studies of prostate-specific antigen declines following enzalutamide in men with metastatic castration-resistant prostate cancer previously treated with docetaxelAndrew J Armstrong, Fred Saad, De Phung, et al.
British Journal of Cancer|November 8, 2022
Extensive metabolic consequences of human glycosyltransferase gene knockouts in prostate cancerMichèle Rouleau, Flora Nguyen Van Long, Véronique Turcotte, et al.
Pageof 113